Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc.

Biotechnology • Healthcare • Irvine, CA, United States • TARS (NMS)

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

949 409 1801 15440 Laguna Canyon Road, Irvine, CA 92618, United States

Stock Performance (90 Days)

Data through Dec 30, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Tarsus Pharmaceuticals Inc (TARS) Q3 2025 Earnings Call Highlights: Record Sales and Strategic ... - Yahoo Finance
Yahoo Finance • Nov 4
Tarsus Pharmaceuticals stock hits all-time high at 83.67 USD - Investing.com
Investing.com • Dec 8
240,020 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by Capricorn Fund Managers Ltd - MarketBeat
MarketBeat • Dec 28
Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3 (NASDAQ:TARS) - Seeking Alpha
Seeking Alpha • Nov 20
Insider Sell: Dianne Whitfield Sells 7,397 Shares of Tarsus Phar - GuruFocus
GuruFocus • Dec 19

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Tarsus Pharmaceuticals, Inc. had layoffs?
No layoff events have been recorded for Tarsus Pharmaceuticals, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Tarsus Pharmaceuticals, Inc. have?
Tarsus Pharmaceuticals, Inc. has approximately 323 employees.
What industry is Tarsus Pharmaceuticals, Inc. in?
Tarsus Pharmaceuticals, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Tarsus Pharmaceuticals, Inc. a publicly traded company?
Yes, Tarsus Pharmaceuticals, Inc. is publicly traded under the ticker symbol TARS on the NMS. The company has a market capitalization of approximately $3.40 billion.
Where is Tarsus Pharmaceuticals, Inc. headquartered?
Tarsus Pharmaceuticals, Inc. is headquartered in Irvine, CA, United States at 15440 Laguna Canyon Road, Irvine, CA 92618, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.